The efficacy of calcitriol treatment in non-alcoholic fatty liver patients with different genotypes of vitamin D receptor FokI polymorphism

Table 1 Baseline characteristics of the calcitriol and placebo intervention groups

variable	Placebo group(n = 64)	Calcitriol group(n = 64)	p-value
Body weight, kg	83.3 ± 11.7	83.6 ± 13.1	0.88
BMI, kg/m²	29.3 ± 3.8	29.0 ± 4.7	0.67
WC, cm	101.8 ± 10.8	100.5 ± 8.8	0.44
HC, cm	107.2 ± 7.7	106.8 ± 9.2	0.78
FBS, mg/dl	94.2 ± 23.0	98.1 ± 38.3	0.49
Insulin, μIU/ml	10.8 ± 5.5	9.6 ± 4.8	0.17
Homa-IR	2.1 ± 0.9	2.0 ± 0.8	0.43
Quicki	0.33 ± 0.03	0.34 ± 0.03	0.54
HS Index	41.4 ± 5.8	41.4 ± 5.6	0.95
APRI index (IQR)	0.30 (0.22–0.38)	0.28 (0.23–0.37)	0.16
TC, mg/dl	188.0 ± 60.9	187.8 ± 46.5	0.98
TG (IQR),mg/dl	168.0 (121.5–210.5)	170.0 (134.0–236.0)	0.32
HDL cholesterol, mg/dl	41.4 ± 11.2	38.3 ± 7.9	0.07
LDL cholesterol, mg/dl	97.9 ± 27.5	96.6 ± 25.9	0.77
AST,IU	29.2 ± 15.6	27.1 ± 8.7	0.35
ALT (IQR), IU	45.5 (32.8–57.0)	23.0 (33.5–51.0)	0.53
GGT, IU	35.2 ± 17.8	37.2 ± 21.7	0.57
ALK, IU	200.2 ± 52.6	197.3 ± 54.9	0.76
Vitamin D, ng/ml	17.5 ± 7.7	19.1 ± 9.6	0.29
Hs-CRP (IQR), μg/ml	2.9 (1.1–5.5)	2.2 (1.1–4.8)	0.99
Leptin (IQR), ng/ml	11.6 (6.6–19.7)	9.9 (5.5–22.5)	0.30
Adiponectin (IQR), μg/ml	18.6 (13.6–28.2)	18.0 (10.8–24.4)	0.89

Values are expressed as the mean ± SD or median (IQR). IQR interquartile range, BMI Body mass index, WC Waist circumference, HC Hip circumference, FBS Fasting blood glucose, Homa-IR Homeostatic Model Assessment for Insulin Resistance, HS index Hepatic steatosis index, APRI AST to Platelet Ratio Index, TC total cholesterol, TG Triglyceride, HDL-c High-density lipoproteins- cholesterol, LDL-c Low density lipoprotein- cholesterol, AST aspartate aminotransferase, ALT Alanine aminotransferase, GGT Gamma-glutamyl transferase, ALK Alkaline phosphatase, Hs-CRP High-sensitivity C-reactive protein

ISSN: 2050-6511